Literature DB >> 9607328

Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.

R H Crosbie1, H Yamada, D P Venzke, M P Lisanti, K P Campbell.   

Abstract

The dystrophin-glycoprotein complex is a multi-subunit protein complex that spans the muscle plasma membrane (sarcolemma) and forms a link between the intracellular cytoskeleton and the extracellular matrix. Caveolin-3, the muscle specific form of caveolin, is also a major structural and regulatory integral membrane protein found at the sarcolemma. Oligomers of caveolin-3 form the structural framework for small membrane pockets known as caveolae. We directly examined whether caveolin-3 is an integral component of the dystrophin-glycoprotein complex by examining four common biochemical and cellular properties of proteins integrally bound to the dystrophin-glycoprotein complex. We found that caveolin-3 de-enriches with partial purification of the dystrophin-glycoprotein complex although a small amount of caveolin-3 is present. Sucrose gradient fractionation and laminin affinity chromatography completely separate this residual caveolin-3 from the core components of the dystrophin-glycoprotein complex. We also show that caveolin-3 expression at the sarcolemma is not reduced in patients with primary mutations in either dystrophin or the sarcoglycans. This data demonstrates that localization of caveolin-3 to the sarcolemma occurs independently of the dystrophin-glycoprotein complex and that caveolin-3 is not an integral component of the dystrophin-glycoprotein complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607328     DOI: 10.1016/s0014-5793(98)00442-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse.

Authors:  J M Gillis
Journal:  J Muscle Res Cell Motil       Date:  1999-10       Impact factor: 2.698

2.  Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Authors:  Masahiko Hoshijima; Takeharu Hayashi; Young E Jeon; Zhenxing Fu; Yusu Gu; Nancy D Dalton; Mark H Ellisman; Xiao Xiao; Frank L Powell; John Ross
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

3.  Over-expression of Microspan, a novel component of the sarcoplasmic reticulum, causes severe muscle pathology with triad abnormalities.

Authors:  Gaynor Miller; Angela K Peter; Erica Espinoza; Jim Heighway; Rachelle H Crosbie
Journal:  J Muscle Res Cell Motil       Date:  2006-07-04       Impact factor: 2.698

Review 4.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

5.  Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.

Authors:  Daniela Volonte; Aaron J Peoples; Ferruccio Galbiati
Journal:  Mol Biol Cell       Date:  2003-08-07       Impact factor: 4.138

6.  Lipid raft in cardiac health and disease.

Authors:  Manika Das; Dipak K Das
Journal:  Curr Cardiol Rev       Date:  2009-05

7.  PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.

Authors:  Marie Feron; Laetitia Guevel; Karl Rouger; Laurence Dubreil; Marie-Claire Arnaud; Mireille Ledevin; Lynn A Megeney; Yan Cherel; Vehary Sakanyan
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

Review 8.  Caveolinopathies: from the biology of caveolin-3 to human diseases.

Authors:  Elisabetta Gazzerro; Federica Sotgia; Claudio Bruno; Michael P Lisanti; Carlo Minetti
Journal:  Eur J Hum Genet       Date:  2009-07-08       Impact factor: 4.246

Review 9.  Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

Authors:  David G Allen; Nicholas P Whitehead; Stanley C Froehner
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

10.  The ZZ domain of dystrophin in DMD: making sense of missense mutations.

Authors:  Adeline Vulin; Nicolas Wein; Dana M Strandjord; Eric K Johnson; Andrew R Findlay; Baijayanta Maiti; Michael T Howard; Yuuki J Kaminoh; Laura E Taylor; Tabatha R Simmons; Will C Ray; Federica Montanaro; Jim M Ervasti; Kevin M Flanigan
Journal:  Hum Mutat       Date:  2013-12-02       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.